Boston Scientific Corporation (NYSE:BSX) does about 9.38M shares in volume on a normal day but saw 7452937 shares change hands in Monday trading. The company now has a market cap of 58.33B USD and an enterprise value of about $66.41B. Its current market price is $41.02, marking a decrease of -0.02% compared to the previous close of $41.03. The 52 week high reached by this stock is $46.62 whilst the lowest price level in 52 weeks is $24.10. The script in recent trading has seen the stock touch a high of $41.24 and a low of $40.74.
Boston Scientific Corporation (BSX) has a 20-day trading average at $39.25 and the current price is -12.01% off the 52-week high compared with 70.21% distance from its 52-week low. The 50-day simple moving average of the closing price is $37.50 and its 200-day simple moving average is $38.62. If we look at the stock’s price movements over the week, volatility stands at 2.20%, which decreases to 1.90% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 67.41 to suggest the stock is neutral.
24 analysts observing the Boston Scientific Corporation (BSX) stock have set the 12-month price targets for the company’s shares at between $43.00 and $50.00. The consensus objective for the share price is $46.23, suggesting that the stock has a potential upside of 11.27% over the period. The median price target is 11.78% away from the current levels at $46.50.
FactSet Research has provided data showing that 24 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 20 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 22, 2020 when SVB Leerink downgraded the stock to “Mkt Perform” and issued a price target of $40. Goldman upgraded the stock to “Buy” from Neutral on April 01, 2020 at a price target of $46-$38. Citigroup initiated its price target at $48.
The current price level is 4.92%, 9.64%, and 6.21% away from its SMA20, SMA50, and SMA200 respectively, with the BSX price moving above the 50-day SMA on August 31. Boston Scientific Corporation (BSX) stock is up 5.34% over the week and 6.35% over the past month. Its price is -9.29% year-to-date and -4.00% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of $0.08 above consensus estimates by $0.1. The company’s next earnings report is expected on 10/21/2020, with forecasts estimating quarterly EPS at $0.24 and $1.01 for whole year. BSX’s earnings per share are forecast to shrink by -36.10% this year and 64.40% over next year. Expected sales for next quarter are $2.97 billion, which analysts say will come at $10.06 billion for the current fiscal year and next year at $11.91 billion. In addition, estimates put the company’s current quarterly revenue at an average of $2.51 billion.
Its 12-month price target is $46.50. To reach the target analysts have set, the stock logically needs to grow 11.27 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $43.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $50.00.
Outstanding shares total 1.43B with insiders holding 0.24% of the shares and institutional holders owning 95.35% of the company’s common stock. The company has a return on investment of 6.00% and return on equity of 30.00%. The forward price to earnings ratio is 24.68. The beta has a value of 0.95. Price to book ratio is 3.71 and price to sales ratio is 5.74.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Boston Scientific Corporation (BSX) to 40,534,156 shares, mirroring a recent drop by -0.18%. Vanguard Total Stock Market Index dumped 71486.0 shares of Boston Scientific Corporation common stock bringing its total worth to about $1.56 billion at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Health Care Fund, which added 4.43 million shares to end up with 36,684,218 shares worth $1.41 billion. Vanguard 500 Index Fund cut their holdings by -0.58% in the company over the course of the most recent quarter. It now holds a 2.06% position in Boston Scientific Corporation thanks to 29.46 million shares amounting to $1.14 billion.